{"id":41835,"date":"2025-09-18T20:47:58","date_gmt":"2025-09-18T12:47:58","guid":{"rendered":"https:\/\/flcube.com\/?p=41835"},"modified":"2025-09-18T20:47:59","modified_gmt":"2025-09-18T12:47:59","slug":"gensci-secures-exclusive-rights-to-alks-house-dust-mite-allergy-therapies-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41835","title":{"rendered":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China"},"content":{"rendered":"\n<p><strong>Changchun GeneScience Pharmaceutical Co., Ltd.<\/strong> (GenSci) announced a strategic partnership with <strong>ALK (ALKB:DC \/ OMX: ALK B)<\/strong> to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable <strong>Alutard HDM<\/strong>, skin\u2011prick tests, and the <strong>ACARIZAX<\/strong> sublingual tablet through the end of 2039.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-highlights\">Partnership Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Distribution<\/strong>: GenSci obtains sole mainland China rights to Alutard HDM, associated diagnostic tests, and ACARIZAX.<\/li>\n\n\n\n<li><strong>Marketing &amp; Development<\/strong>: GenSci will cover all marketing, sales, and the majority of clinical\u2011development and registration costs; ALK will supply and manufacture the products.<\/li>\n\n\n\n<li><strong>Immediate Roll\u2011out<\/strong>: Alutard sales begin immediately, with ACARIZAX added to GenSci\u2019s portfolio upon regulatory approval.<\/li>\n\n\n\n<li><strong>Joint Clinical Development<\/strong>: Both parties will finalise ongoing clinical studies to expedite ACARIZAX approval for adults and children.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Up\u2011front Payment<\/strong>: DKK\u202f\u2248\u202f245\u202fmillion to ALK.<\/li>\n\n\n\n<li><strong>Regulatory Milestones<\/strong>: Up to DKK\u202f\u2248\u202f300\u202fmillion tied to ACARIZAX approval (2028\u20112030).<\/li>\n\n\n\n<li><strong>Commercial Milestones<\/strong>: Up to DKK\u202f\u2248\u202f780\u202fmillion contingent on future in\u2011market sales in Mainland China.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access<\/strong>: The partnership positions GenSci to capture the growing Chinese AIT market, estimated to exceed <strong>US$1\u202fbillion<\/strong> by 2030.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong>: Adding ACARIZAX to GenSci\u2019s product line diversifies its offerings beyond injectable therapies.<\/li>\n\n\n\n<li><strong>Collaborative Development<\/strong>: Joint clinical efforts may shorten time\u2011to\u2011approval, providing a competitive edge over other AIT providers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41836,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11,22],"tags":[358],"class_list":["post-41835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","category-medical-device","tag-genescience-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41835\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China\" \/>\n<meta property=\"og:description\" content=\"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41835\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-18T12:47:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-18T12:47:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China\",\"datePublished\":\"2025-09-18T12:47:58+00:00\",\"dateModified\":\"2025-09-18T12:47:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1812.webp\",\"keywords\":[\"GeneScience Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41835#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41835\",\"name\":\"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1812.webp\",\"datePublished\":\"2025-09-18T12:47:58+00:00\",\"dateModified\":\"2025-09-18T12:47:59+00:00\",\"description\":\"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \\\/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41835\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1812.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1812.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41835#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41835","og_locale":"en_US","og_type":"article","og_title":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China","og_description":"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.","og_url":"https:\/\/flcube.com\/?p=41835","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-18T12:47:58+00:00","article_modified_time":"2025-09-18T12:47:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41835#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41835"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China","datePublished":"2025-09-18T12:47:58+00:00","dateModified":"2025-09-18T12:47:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41835"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41835#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","keywords":["GeneScience Pharmaceutical"],"articleSection":["Company","Deals","Drug","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41835#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41835","url":"https:\/\/flcube.com\/?p=41835","name":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41835#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41835#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","datePublished":"2025-09-18T12:47:58+00:00","dateModified":"2025-09-18T12:47:59+00:00","description":"Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC \/ OMX: ALK B) to develop and commercialise ALK\u2019s house\u2011dust\u2011mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK\u2019s injectable Alutard HDM, skin\u2011prick tests, and the ACARIZAX sublingual tablet through the end of 2039.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41835#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41835"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41835#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","width":1080,"height":608,"caption":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41835#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenSci Secures Exclusive Rights to ALK\u2019s House Dust Mite Allergy Therapies in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1812.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41835"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41835\/revisions"}],"predecessor-version":[{"id":41837,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41835\/revisions\/41837"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41836"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}